论文部分内容阅读
目的探讨舒利迭治疗COPD稳定期的疗效及其安全性。方法纳入COPD稳定期患者80例,随机分为两组,观察组和对照组各40例,观察组采用舒利迭治疗,对照组采用常规治疗,治疗3个月,观察两组症状、体征和肺功能改善情况。结果治疗后观察组总有效率明显优于对照组(P<0.05);治疗后观察组FEV1、FEV1%和FEV1/FVC改善明显优于对照组(P<0.05);两组患者均未出现严重不良反应。结论沙美特罗/丙酸氟替卡松干粉剂能有效改善COPD稳定期患者的症状、体征和肺功能,临床疗效确切,安全性好,值得基层医院推广应用。
Objective To investigate the efficacy and safety of seretide in the treatment of stable COPD. Methods Eighty patients with stable COPD were enrolled in this study. They were randomly divided into two groups: observation group (40 cases) and control group (40 cases). Patients in the observation group were treated with seretide, while those in the control group were treated by conventional therapy for 3 months. Symptoms and signs Pulmonary function improvement. Results After treatment, the total effective rate in the observation group was significantly better than that in the control group (P <0.05). After treatment, the improvement of FEV1, FEV1% and FEV1 / FVC in the observation group was significantly better than that in the control group (P <0.05) Adverse reactions. Conclusions Salmeterol / fluticasone propionate dry powder can effectively improve the symptoms, signs and lung function in patients with stable COPD. The clinical efficacy is good and the safety is good. It is worth popularizing and applying in primary hospitals.